DesigneRx Pharmaceuticals

DesigneRx Pharmaceuticals was a specialty pharmaceutical company focused on the development of proprietary inhaled formulations of off-patent drugs. The company's core expertise lay in optimizing the delivery of existing therapeutics to the lungs for the treatment of respiratory and systemic diseases. By utilizing advanced formulation technologies, DesigneRx aimed to improve the therapeutic index and patient convenience of established medications. In February 2002, DesigneRx was acquired by Inhale Therapeutic Systems (now Nektar Therapeutics) in an all-stock transaction valued at approximately $20 million. This acquisition allowed Nektar to expand its internal pipeline of inhaled products, including early-stage programs for inhaled anti-infectives like amphotericin B. Following the acquisition, the company's operations and technology were integrated into Nektar's pulmonary delivery platform.